This week in techniques



Licensing status

Publication and contact information

Disease models

Mouse model for proteolytic clearance of plasma b-amyloid (Ab)

Mouse studies suggest reducing plasma Ab levels may not be sufficient to decrease Ab in the CNS. Reducing plasma Ab levels has been suggested as a strategy to decrease CNS Ab by acting as an efflux sink for the peptide. In both wild-type mice and a mouse model for Ab-driven Alzheimer's disease (AD), peripheral infusion of recombinant neutral endopeptidase (neprilysin; MME; NEP; CD10), an Ab-cleaving metalloprotease, decreased plasma Ab levels compared with saline infusion but did not decrease Ab levels in the brain and cerebrospinal fluid. Researchers did not disclose next steps, which could include replicating the studies with other classes of compounds that deplete peripheral Ab levels.

SciBX 6(7); doi:10.1038/scibx.2013.175
Published online Feb. 21, 2013

Patent and licensing status undisclosed

Walker, J.R. et al. J. Neurosci.;
published online Feb. 6, 2013;
Contact: Andrew M. Schumacher, Genomics Institute of the Novartis Research Foundation, San Diego, Calif.